Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 25Lymphoma, Follicular 24Multiple Myeloma 22Lymphoma, B-Cell, Marginal Zone 21Leukemia 21Lymphoma, Non-Hodgkin 19Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Hematologic Neoplasms 16Waldenstrom Macroglobulinemia 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 12Congenital Abnormalities 11Burkitt Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 10Mycosis Fungoides 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Sezary Syndrome 8Recurrence 8Hodgkin Disease 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Plasma Cell 6Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6

Interventions

Dexamethasone 3filanesib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2pomalidomide 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Gemcitabine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Bortezomib × Other hematologic neoplasm × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡